Tenax Therapeutics, Inc.
TENX
$5.71
$0.142.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 79.26% | 12.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 57.93% | 25.79% | |||
| Operating Income | -57.93% | -25.79% | |||
| Income Before Tax | -58.24% | -10.76% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -58.24% | -10.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -58.24% | -10.76% | |||
| EBIT | -57.93% | -25.79% | |||
| EBITDA | -57.96% | -25.80% | |||
| EPS Basic | 5.13% | 89.75% | |||
| Normalized Basic EPS | 5.13% | 89.75% | |||
| EPS Diluted | 5.13% | 89.75% | |||
| Normalized Diluted EPS | 5.13% | 89.75% | |||
| Average Basic Shares Outstanding | 66.79% | 980.64% | |||
| Average Diluted Shares Outstanding | 66.79% | 980.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||